{"id":3831,"date":"2019-04-15T12:02:45","date_gmt":"2019-04-15T10:02:45","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/"},"modified":"2020-06-26T14:12:01","modified_gmt":"2020-06-26T12:12:01","slug":"nanexa-har-haft-en-bra-start-pa-aret","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/","title":{"rendered":"Nanexa har haft en bra start p\u00e5 \u00e5ret"},"content":{"rendered":"
\n

<\/strong><\/span><\/p>\n<\/div>\n

F\u00f6rsta kvartalet av 2019 har varit ett intensivt kvartal f\u00f6r oss p\u00e5 Nanexa. I och med de tre avtalen vi skrev i slutet av f\u00f6reg\u00e5ende \u00e5r har vi varit fullt upptagna med att leverera i de samarbetena. Vi har ytterligare aktiviteter att utf\u00f6ra f\u00f6r att avsluta dessa initiala utv\u00e4rderingar av PharmaShell\u00ae\u00a0f\u00f6r respektive bolags aktiva substanser, men diskussioner p\u00e5g\u00e5r redan om m\u00f6jliga forts\u00e4ttningar.<\/span><\/p>\n

Arbetet med AstraZeneca p\u00e5g\u00e5r ocks\u00e5 enligt plan och d\u00e4r har ytterligare en djurstudie startats i deras regi som ett led i den breddning av samarbetet som kommunicerades under h\u00f6stan 2018.<\/span><\/p>\n

Parallellt med det ovan n\u00e4mnda har vi arbetat vidare i NEX-18 projektet. Vi har genomf\u00f6rt v\u00e5r f\u00f6rsta djurstudie med PharmaShell\u00ae-coatad azacitidin och i den genererat v\u00e4rdefull data f\u00f6r att kunna optimera PharmaShell\u00ae-processen till den m\u00e5lbild f\u00f6r fris\u00e4ttning vi har.<\/span><\/p>\n

Arbetet f\u00f6r att ta fram regulatorisk och klinisk utvecklingsstrategi f\u00f6r NEX-18 p\u00e5g\u00e5r b\u00e5de f\u00f6r den europeiska och amerikanska marknaden. V\u00e5r m\u00e5ls\u00e4ttning \u00e4r att skapa en s\u00e5 kort och kostnadseffektiv utvecklingsplan som m\u00f6jligt.<\/span><\/p>\n

P\u00e5 laboratoriet i Uppsala har vi ocks\u00e5 under f\u00f6rsta kvartalet installerat v\u00e5r tredje ALD-reaktor samt ut\u00f6kat v\u00e5r kapacitet med ytterligare analytisk utrustning. Vi har nu ocks\u00e5 f\u00f6rst\u00e4rkt v\u00e5r grupp med ytterligare en medarbetare med masterexamen i materialkemi, som kommer f\u00f6rst\u00e4rka v\u00e5r kacapitet f\u00f6r utvecklingen av PharmaShell\u00ae.<\/span><\/p>\n

P\u00e5 den kommersiella sidan har vi hunnit med tv\u00e5 konferenser; dels Drug Delivery Partnerships i Florida i januari och dels BIO-Europe i Wien i mars. Under konferenserna har vi haft flertalet bra m\u00f6ten och diskussioner med intressanta l\u00e4kemedelsf\u00f6retag.<\/span><\/p>\n

Det kan ocks\u00e5 n\u00e4mnas att Nanexa och PharmaShell\u00ae\u00a0nu f\u00f6r f\u00f6rsta g\u00e5ngen belysts i en global marknadsanalys \u00f6ver nya drug delivery-teknologier f\u00f6r biologics –\u00a0\u201dNovelTechnologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030\u201d(Roots analysis, Business research and consulting).<\/span><\/p>\n

Nanexas VD David Westberg kommenterar:\u00a0Det har varit en riktigt bra start p\u00e5 \u00e5ret och riktigt roligt att vi blir uppm\u00e4rksammade i externa marknadsrapporter.\u00a0Gl\u00e4djande \u00e4r att det g\u00e5tt riktigt bra i de samarbeten vi har och att vi kunnat leverera enligt \u00f6verenskomna planer med samarbetsparnerna.Jag k\u00e4nner stor tillf\u00f6rsikt att resten av \u00e5ret kommer f\u00f6lja i samma positiva riktning.<\/span><\/p>\n

F\u00f6r mer information kontakta:
David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ)\u00a0Telefon: 0709 – 42 83 03
E-post: david.westberg@nanexa.se www.nanexa.com<\/span><\/p>\n

Om Nanexa AB (publ)<\/span><\/p>\n

Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae\u00a0har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n

<\/p>\n

<\/strong><\/span><\/p>\n

<\/p>\n

<\/strong><\/span><\/p>\n

\n

Bifogade filer<\/strong><\/p>\n\n

L\u00e4s som pdf<\/a><\/p>\n<\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n

F\u00f6rsta kvartalet av 2019 har varit ett intensivt kvartal f\u00f6r oss p\u00e5 Nanexa. I och med de tre avtalen vi skrev i slutet av f\u00f6reg\u00e5ende \u00e5r har vi varit fullt upptagna med att leverera i de samarbetena.<\/p>\n

L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3831","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa har haft en bra start p\u00e5 \u00e5ret - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa har haft en bra start p\u00e5 \u00e5ret - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"F\u00f6rsta kvartalet av 2019 har varit ett intensivt kvartal f\u00f6r oss p\u00e5 Nanexa. I och med de tre avtalen vi skrev i slutet av f\u00f6reg\u00e5ende \u00e5r har vi varit fullt upptagna med att leverera i de samarbetena.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-26T12:12:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-haft-en-bra-start-pa-aret\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-haft-en-bra-start-pa-aret\\\/\",\"name\":\"Nanexa har haft en bra start p\u00e5 \u00e5ret - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2019-04-15T10:02:45+00:00\",\"dateModified\":\"2020-06-26T12:12:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-haft-en-bra-start-pa-aret\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-haft-en-bra-start-pa-aret\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-haft-en-bra-start-pa-aret\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa har haft en bra start p\u00e5 \u00e5ret\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa har haft en bra start p\u00e5 \u00e5ret - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa har haft en bra start p\u00e5 \u00e5ret - Nanexa AB","og_description":"F\u00f6rsta kvartalet av 2019 har varit ett intensivt kvartal f\u00f6r oss p\u00e5 Nanexa. I och med de tre avtalen vi skrev i slutet av f\u00f6reg\u00e5ende \u00e5r har vi varit fullt upptagna med att leverera i de samarbetena.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/","og_site_name":"Nanexa AB","article_modified_time":"2020-06-26T12:12:01+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/","name":"Nanexa har haft en bra start p\u00e5 \u00e5ret - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2019-04-15T10:02:45+00:00","dateModified":"2020-06-26T12:12:01+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-haft-en-bra-start-pa-aret\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa har haft en bra start p\u00e5 \u00e5ret"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}